Compugen Postpones Issuance of Third Quarter 2012 Report & Associated Conference Call to November 5, 2012, Due to Expected Se...
October 29 2012 - 9:23AM
Business Wire
Compugen Ltd. (NASDAQ:CGEN) announced today the postponement of
both the issuance of its Third Quarter 2012 Financial Results
Report and conference call with investors to Monday, November 5,
2012 at 10 a.m. ET. The issuance of the report and the call
were previously planned for Tuesday, October 30, 2012 at 10 a.m.
ET, and have been rescheduled due to the expected severe weather
conditions associated with Hurricane Sandy.
The purpose of the call is to review third quarter 2012 results.
The quarterly results will be released on the Company’s website
(www.cgen.com), prior to the conference call.
To access the conference call on Monday, November 5, 2012 at
10 a.m. ET, please dial 1-888-668-9141 from the US, or +
972-3-918-0609 internationally. The call will also be available via
live webcast through Compugen’s website, located at the following
link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-782-4291 from the US or
+972-3-925-5904 internationally. The replay will be available
through November 8, 2012.
About Compugen
Compugen is a leading therapeutic product discovery company
focused on therapeutic proteins and monoclonal antibodies to
address important unmet needs in the fields of immunology and
oncology. Unlike traditional high throughput trial and error
experimental based drug candidate discovery, Compugen utilizes a
broad and continuously growing infrastructure of proprietary
scientific understandings and predictive platforms, algorithms,
machine learning systems and other computational biology
capabilities for the in silico (by computer) prediction and
selection of product candidates. Selected product candidates are
then advanced in its Pipeline Program to the pre-IND stage. The
Company's business model primarily involves collaborations covering
the further development and commercialization of product candidates
from its Pipeline Program and various forms of research and
discovery agreements, in both cases providing Compugen with
potential milestone payments and royalties on product sales or
other forms of revenue sharing. In 2012, Compugen established
operations in California for the development of oncology and
immunology monoclonal antibody therapeutic candidates against
Compugen-discovered drug targets. In 2002, Compugen established an
affiliate, Evogene Ltd. (www.evogene.com) (TASE:EVGN.TA), to
utilize certain of the Company's in silico predictive discovery
capabilities in agricultural biotechnology. For additional
information, please visit Compugen's corporate website at
www.cgen.com.
This press release may contain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as “may”, “expects”,
“anticipates”, “believes”, and “intends”, and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
discussed in the "Risk Factors" section Compugen’s Annual Report on
Form 20-F for the year ended December 31, 2011 as filed with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024